Redhill Biopharma ($RDHL)

Stock Image

RDHL Overview

RedHill Biopharma, a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases.The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.Its clinical late-stage investigational development programs include RHB-204, with a planned Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), a SK2 selective inhibitor targeting various indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and in Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, a Phase 2-stage serine protease inhibitor for cancer and inflammatory gastrointestinal diseases, and is also being evaluated for COVID-19; and RHB-106, an encapsulated bowel preparation.The company was founded in 2009 and is headquartered in Tel Aviv, Israel. (From: StockAnalysis.com)

MORE ABOUT Redhill Biopharma

Stay up to date with the best of Bullish each week.


Stay up to date with the best of Bullish each week.